Cadrenal Therapeutics
CVKD
2 hedge funds and large institutions have $68 invested in Cadrenal Therapeutics in 2024 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 8 closing their positions.
0.14% less ownership
Funds ownership: 0.15% → 0% (-0.14%)
78% less funds holding
Funds holding: 9 → 2 (-7)
88% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 8
100% less capital invested
Capital invested by funds: $165K → $68 (-$165K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$201 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APP
Avantax Planning Partners
Dubuque,
Iowa
|
-$53.3K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$28.9K |
| 3 |
Renaissance Technologies
New York
|
-$28K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$25.6K |
| 5 |
VF
Virtu Financial
New York
|
-$12K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Bank of America
Charlotte,
North Carolina
| $68 | – | – | – |
|
|
APP
2
Avantax Planning Partners
Dubuque,
Iowa
| – | -$53.3K | -7,554 | Closed |
|
|
3
Geode Capital Management
Boston,
Massachusetts
| – | -$28.9K | -4,104 | Closed |
|
|
4
Renaissance Technologies
New York
| – | -$28K | -3,966 | Closed |
|
|
5
Citadel Advisors
Miami,
Florida
| – | -$25.6K | -3,636 | Closed |
|
|
VF
6
Virtu Financial
New York
| – | -$12K | -1,649 | Closed |
|
|
TSS
7
Two Sigma Securities
New York
| – | -$7.45K | -1,057 | Closed |
|
|
BFO
8
Biltmore Family Office
Charlotte,
North Carolina
| – | -$5.17K | -733 | Closed |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| – | -$4.54K | -644 | Closed |
|
|
10
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$201 | +25 | New |
|
CVKD Hedge Fund Activity: Q3 2024 in Review
2 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Cadrenal Therapeutics (CVKD) for Q3 2024, worth a combined $68 — down 100% from $165K a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of CVKD and 1 opened new positions — a net loss of 7 holders — while 0 trimmed existing stakes and 0 added.
The largest buyer was Royal Bank of Canada, opening a new position worth an estimated $201. The largest seller was Avantax Planning Partners, exiting entirely with an estimated $53.3K sold.
- 2 institutional investors held Cadrenal Therapeutics (CVKD) as of Q3 2024, down from 9 in Q2 2024.
- Funds reported $68 of Cadrenal Therapeutics stock for Q3 2024, down 100% quarter-over-quarter.
- 1 fund opened new Cadrenal Therapeutics positions in Q3 2024 and 8 closed out, a net change of -7 holders.
- The largest Cadrenal Therapeutics buyer in Q3 2024 was Royal Bank of Canada, an estimated $201 added.
- The largest Cadrenal Therapeutics seller in Q3 2024 was Avantax Planning Partners, an estimated $53.3K sold.
Based on aggregated 13F filings for Q3 2024.